Sanofi S.A. stock (FR0000127771): Analyst consensus points to hold stance as shares hover in low-40s USD range

Sanofi shares around the low-40s USD mark continue to trade broadly in line with a hold consensus from Wall Street analysts, while the French pharma group remains anchored in its home market on Euronext Paris with secondary trading on Nasdaq via ADRs.

Sanofi shares are trading in the low-40s USD range on Nasdaq via American Depositary Receipts (ADR), with the last quoted close at USD 43.67 on 05/29/2026 according to MarketBeat data, while the primary listing remains on Euronext Paris in France under the ticker SAN.

For investors in the home market France, Sanofi is a heavyweight in the local equity universe, with its ordinary shares quoted in EUR on Euronext Paris and included in major domestic indices such as the CAC 40, underpinning its role as a core large cap name for French and broader European equity portfolios.

According to MarketBeat, as of 05/29/2026 Sanofi’s ADRs on Nasdaq closed at USD 43.67, down 0.62 USD or 1.40% for the session, with after-hours trading showing USD 44.03, implying a modest recovery following regular trading hours.

The same MarketBeat overview highlights that the consensus 12-month price target from 15 Wall Street analysts currently stands at USD 51.00, with individual targets ranging from USD 50.00 to USD 52.00, pointing to a forecasted upside in the mid-teens percentage range from the latest close despite the prevailing hold recommendation.

In valuation terms, data cited by Insider Monkey for Sanofi at a share price of USD 43.67 indicates a price-to-earnings ratio of roughly 19.26, placing the company within a typical range for large-cap global pharmaceutical firms that balance mature cash-generating franchises with late-stage pipeline investment.

From a German investor’s perspective, Sanofi is also accessible on platforms such as Tradegate and the Frankfurt venues via secondary listings and over-the-counter trading, where prices are typically quoted in EUR and often reflect both the Euronext Paris reference price and intraday moves in the EUR/USD exchange rate.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Sanofi
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: Paris, France
• Core markets: Europe, United States, emerging markets
• Key revenue drivers: Specialty care medicines, vaccines, and consumer healthcare products
• Home exchange/listing venue: Euronext Paris (SAN)
• Trading currency: EUR

Sanofi S.A.: core business model

Sanofi focuses on developing and marketing prescription medicines, vaccines, and consumer health therapies across multiple therapeutic areas, with revenue primarily generated from specialty care franchises, immunology, rare diseases, vaccines, and established prescription portfolios sold worldwide.

What banks and research houses say about Sanofi S.A.

MarketBeat’s compilation of broker views as of 05/29/2026 shows that 15 Wall Street analysts covering Sanofi currently assign the stock an overall consensus rating of "Hold", indicating a broadly neutral stance at this stage rather than a strong conviction in either direction.

The same MarketBeat analyst survey lists an average 12-month price target for Sanofi’s Nasdaq-listed ADRs at USD 51.00, with the highest target reported at USD 52.00 and the lowest at USD 50.00, implying an expected upside of approximately 16.78% from the last close of USD 43.67 if those projections were to be realized over the coming year.

Conclusion

Sanofi’s shares, trading around USD 43.67 for the Nasdaq ADR line as of 05/29/2026, reflect a large-cap French pharmaceutical group that remains closely watched in its home market on Euronext Paris and via secondary listings for international investors.

The hold consensus from 15 Wall Street analysts, combined with an average 12-month price target of USD 51.00 that implies mid-teens percentage upside, suggests that the market is weighing Sanofi’s valuation against its pipeline prospects and established franchises without a clear directional conviction.

For equity followers, upcoming company-specific news flow, regulatory outcomes, and any revisions to earnings expectations or analyst views could influence whether the current neutral stance on Sanofi gives way to more differentiated opinions on the stock’s risk-reward profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.